Biotech / Pharmatech

🔥 Teva's Monthly Schizophrenia Shot Skips the Three-Hour Waiting Room

Teva's WELTRUZA, the first once-monthly subcutaneous olanzapine shot, won FDA approval with zero post-injection syndrome cases in trials.

By Tech Arcade··5 min read

Teva's Monthly Schizophrenia Shot Skips the Three-Hour Waiting Room — Tech Arcade
Photo: Ian Talmacs / Unsplash

For more than a decade, olanzapine had a strange reputation in psychiatry: one of the most effective antipsychotics ever made, and one of the most dreaded to inject. The pill worked. The long-acting shot came with a risk scary enough that almost nobody used it. Teva just rewired that trade-off.

Let’s get the number on the table first: 3,470. That’s how many subcutaneous injections of Teva’s new drug WELTRUZA went into patients in the long-term safety analysis with zero confirmed or suspected cases of the dangerous post-injection syndrome that haunted the old formulation (Pharmacy Times).

The FDA signed off on October 9, making WELTRUZA (olanzapine, extended-release injectable suspension) the first and only once-monthly subcutaneous olanzapine cleared for adults with schizophrenia (Teva via Yahoo Finance). One shot a month, no loading dose, no oral top-ups, and — critically — no sitting in a clinic afterward to make sure you don’t pass out.

Here’s the thesis: a drug class people trusted but couldn’t safely inject just became a routine monthly jab, and that quietly reopens the single hardest problem in schizophrenia care.

🧠 Why This Matters

Schizophrenia treatment lives and dies on one thing: whether people keep taking their medication. About 2.2 million Americans have schizophrenia, and roughly 1.5 million are in treatment (Yahoo Finance). Daily pills get missed, and every missed stretch raises the odds of relapse and hospitalization. Long-acting injectables exist precisely to solve that — one shot replaces a month of pills.

The problem was that olanzapine, used by about 19% of patients on oral antipsychotics, had almost no usable injectable version. Its only long-acting shot, Eli Lilly’s Zyprexa Relprevv, was taken by fewer than 0.1% of patients on injectables (Pharmacy Times). The reason was a condition called post-injection delirium/sedation syndrome, or PDSS, where the drug accidentally hits the bloodstream too fast and triggers sudden sedation or delirium.

“Adherence continues to be a major barrier to stability.” — Christoph Correll, MD, SOLARIS coordinating investigator (Pharmacy Times)

📊 Deep Dive

WELTRUZA uses a copolymer delivery technology called SteadyTeq, licensed from France’s MedinCell, that forms a depot under the skin and releases olanzapine in a slow, controlled drip rather than the uncontrolled dissolution of the older formulation (HCPLive). It comes in three monthly doses — 318 mg, 425 mg, and 531 mg — mapping to 10, 15, and 20 mg of daily oral olanzapine.

The approval rests on SOLARIS, a Phase 3 trial of 675 adults aged 18 to 64, randomized across the three doses and placebo for eight weeks, then followed for up to 48 more (HCPLive). All three doses beat placebo on the PANSS symptom scale, with the mid dose showing a placebo-adjusted improvement of −11.27 points and a P-value under .001 (Pharmacy Times). In the roughly year-long second period, Teva reported just a 4% relapse rate (Yahoo Finance).

How the new shot stacks up against the one it’s meant to replace:

  • PDSS risk: Zyprexa Relprevv, roughly 1.4% per patient; WELTRUZA, zero across 3,470 injections in the long-term analysis.
  • Post-injection monitoring: Zyprexa Relprevv required a REMS program with at least three hours of supervised observation at a certified site after every dose; WELTRUZA requires none.
  • Route: old shot, intramuscular; new shot, subcutaneous.
  • Extras: WELTRUZA needs no loading dose and no oral supplementation to reach therapeutic levels.

That three-hour clinic wait, dose after dose, month after month, is a big reason the old injectable effectively died in the market. Removing it is the headline.

⚠️ The Catch

Olanzapine is still olanzapine, and its metabolic baggage comes along for the ride. In the safety analysis, 36% of participants gained weight, and among the 137 people treated for at least 48 weeks, the mean gain was 5.6 kg (Pharmacy Times). Injection-site reactions showed up too — induration and pain in about 12% each.

PDSS is not fully ruled out, either. The label notes the syndrome has occurred with intramuscular extended-release olanzapine and that it isn’t yet known whether it can happen with the subcutaneous version — reassuring trial data, but not a guarantee. WELTRUZA also carries the class boxed warning for increased mortality in elderly patients with dementia-related psychosis, and it isn’t approved for that group.

Then there’s cost. The wholesale acquisition price is $2,950 per month, flat across all three doses (Yahoo Finance). Insurance coverage will decide whether that translates into real-world uptake.

🎯 What Happens Next

Teva expects WELTRUZA on the US market “in the coming weeks,” with some Medicaid coverage potentially starting immediately and other states taking six to 18 months. The company is betting on roughly 85% coverage by the end of the first year (Yahoo Finance).

Financially, this is a load-bearing launch. Teva has guided to combined annual revenue of $1.5 billion to $2 billion for WELTRUZA and its sister long-acting drug UZEDY, and CEO Richard Francis has framed both as central to the company’s “Pivot to Growth” strategy (Yahoo Finance).

“What WELTRUZA will bring, we hope, is that chance of decreasing relapses.” — Eric Hughes, MD, PhD, Teva head of R&D and chief medical officer (Yahoo Finance)

🧩 Bigger Picture

The quiet story here is the delivery platform. MedinCell’s injectable-depot technology is what turned a difficult molecule into a once-a-month product, and it’s the same engine behind UZEDY. If the approach keeps working, expect more familiar daily pills to reappear as monthly shots across psychiatry and beyond — the hard part was never the drug, it was getting it to release at a steady pace.

For patients, the math is simpler. Twelve injections a year instead of 365 pills, using a medicine that clinicians already know inside out, without a mandatory clinic stopover each time. For a condition where staying on treatment is most of the battle, that’s the part that could actually move outcomes.

Olanzapine spent years as the drug doctors reached for and the needle they avoided. Teva’s bet is that fixing the needle was worth more than inventing a new drug.

Sources

❓ Quick answers

What is WELTRUZA and what was it approved for?

WELTRUZA (olanzapine extended-release injectable suspension) from Teva is a once-monthly subcutaneous injection for adults with schizophrenia, approved by the FDA on October 9, 2026 (Yahoo Finance/Teva).

How much does WELTRUZA cost?

Its wholesale acquisition cost is $2,950 per month, flat across all three doses (318 mg, 425 mg, 531 mg), per Teva via Yahoo Finance, October 2026.

Is WELTRUZA safer than the older olanzapine injection?

In the SOLARIS long-term analysis there were zero post-injection syndrome cases across 3,470 injections, versus roughly 1.4% with the older intramuscular depot that required a three-hour supervised wait, per Pharmacy Times (October 2026).